Suspected or confirmed active TB disease
Known allergies to any of the study medications by participant self-report
have a positive pregnancy test at screening, or
are not willing to use a reliable method of barrier contraception during the study, or
are breastfeeding
hormonal contraception
HIV infected participants who are on anti-retroviral drugs
other drugs that interact with 3HP (see Table 1)
Known contact with an INH or rifampin resistant case
Weight < 10 kg
Evidence of possible liver damage defined by an aspartate transaminase (AST) level that is more than 3x the upper limit of normal in an asymptomatic patient
Porphyria reported by patient
Inability to adhere to protocol.
Patients may be excluded from the study for other reasons, at the investigator's discretion with detailed documentation.

NCT02689089_exc_T1
Condition
active TB
NCT02689089_exc_T2
Condition
allergies
NCT02689089_exc_T7
Procedure
hormonal contraception
NCT02689089_exc_T8
Condition
HIV infected
NCT02689089_exc_T9
Drug
anti-retroviral drugs
NCT02689089_exc_T11
Condition
resistant
NCT02689089_exc_T12
Drug
rifampin
NCT02689089_exc_T13
Drug
INH
NCT02689089_exc_T14
Scope
INH or rifampin
NCT02689089_exc_T15
Measurement
Weight
NCT02689089_exc_T16
Value
< 10 kg
NCT02689089_exc_T17
Condition
liver damage
NCT02689089_exc_T18
Measurement
aspartate transaminase
NCT02689089_exc_T19
Measurement
AST
NCT02689089_exc_T20
Value
more than 3x the upper limit of normal
NCT02689089_exc_T21
Condition
Porphyria